

Subject Index

Italic page numbers indicate figures; page number followed by “t” indicate tables.

A

Accreditation Council for Continuing Medical Education (ACCME), 7
Accreditation Council for Graduate Medical Education, 45, 66, 67
Acromegaly, 18, 21
Activa RC, 11
Active learning, process of, 57
Acyclovir, for cold sores, 74
Adaptive trial designs, 38–39
Advocacy, for health policy, 71
“Aequanimitas” (Osler), 7
All-or-none diseases, 54
Ambulatory Care Quality Alliance, 47
American Association of Neurological Surgeons (AANS), 46, 66
American Association of Retired Persons (AARP), 47
American Board of Medical Specialties (ABMS), 7, 45, 66, 67
American Board of Neurological Surgery (ABNS), 45, 68
American Board of Pediatric Neurological Surgery, 67
American Medical Association (AMA), 46
L-Amino acid decarboxylase, 14
5-Aminolevulinic acid (ALA), 93–97, 95
Amyotrophic lateral sclerosis (ALS), 132
Anaplastic astrocytoma (AA), 95, 99
Anaplastic mixed oligodendroglioma, 99
Anaplastic oligodendroglioma, 99
Anecdotal experience, as evidence, 25
Animal models
 Drosophila, neuromodulation studies, 14
 mouse
 of intracerebral tumors, 102–105, 103, 104
 of spinal cord contusion, 85
 U87 cell xenografts, 111, 114
 rat, for ALS, 132
Annual meetings, learning through, 5
Anorexia, DBS for, 9
Anticonvulsant therapy, 74
Arcadis Orbic system, 21
Arteriovenous malformations (AVMs)
 classification of, 41
 distribution of patients based on, 42t
 grade I, 41
 grade II, 41
 grade III, 41–44
 grade IIIA, 42
 grade IIIB, 42
 grade IIIC, 43
 grade IV, 43
 grade V, 43, 43–44
 outcomes and, 41–44
 surgical results, 42t, 43t
 treatment strategies and, 41t
 diagnosis, 41
 exposure of, 41
 microsurgical resection in, 40

 MRI imaging of surgical outcomes, 42t
 patient selection, 40–41
 residual, 44
 saccular aneurysms associated with, 41
 supratentorial, 40–44
 treatment, 40, 44
Asher, Anthony, 49, 53
Assessments, instructional methodology studies, 59
Astrocytomas, IHC staining, 99
Autonomic function assessment, 86, 88–89, 89, 90
Autonomy
 of patients, 35t
 principle of, 34

B

Bacterial artificial chromosome (BAC)
 expressing green fluorescent protein, 125
 Hb9::GFP transfection, 125, 131
 transfection protocol, 127
Bacterial artificial chromosome—transgenic hESC cell line
 characterization of, 126, 128
 differentiation to motor neuron lineage, 128
 electrophysical analysis, 127
 immunofluorescence studies, 127
 microscopy studies, 127
 PCR analysis, 127, 130
 results, 127–130
 transcriptome analysis, 127
Balloon compression, injury caused by, 73–74
Barkan, Ariel, 18
Basso, Beattie, Bresnahn locomotor scale, 87–88, 87t, 88
Basso Mouse scale (BMS), 86, 87–88, 87t, 89
Bayesian trial designs, 38–39
B16EGFRvIII cells, 102, 103, 103, 104
Beliefs, knowledge and, 59
Belmont report, 34
Beneficence, principle of, 34, 35t
Benzel. E.C., 49–53
Biases
 core ideologies and, 50–51
 forms of, 51
 risk in meta-analyses, 29
 in study design, 27
 unpredictability paradox and, 27
Bipolar cauterization, 41
Bleeding, control of, 41
Blinding
 definition, 27
 in surgical RCTs, 28
Bortezomib (Velcade)
 cell culture studies, 108, 109
 cell fate after TMZ and, 113–114
 delayed treatment with, 113–114
 effect on U87 cell xenografts, 114, 115

growth arrest study, 110
 sensitizing effect of, 116–117
 TMZ treatment with, 113
 Bosk, Charles, 35
 Bovie devices, 20
 Bradycardia, trigeminal nerve compression and, 74
 Bread mold colony, 50
 Bridges to Excellence, 46
Built to Last (Collins and Porras), 51

C

Cabergoline, 21
 α -CamKII promoter, 15
 Cannabinoid CB₁ receptor
 function of, 84–85
 inhibition of, 84–92
 localization of, 84
 mechanism of action, 84
 Cannabinoid CB₂ receptor
 activation of, 84–92, 85
 localization of, 85
 mechanism of action, 84
 Cannabinoids
 clinical applications for, 84
 terminology, 84
Cannabis sativa, 84
 Carbamazepine, 74
 Case reports, as evidence, 24–25
 Case series
 as evidence, 24–25
 with external controls, 25–27
 with internal controls, 25–27
 uncontrolled, 24–25
 Catheters, antibiotic-impregnated, 11
 CD8, IHC staining, 99
 Census sessions, 5
 Central Brain Tumor Registry, 18
 Cerebral hemorrhages, intraparenchymal, 44
 Cerebrospinal fluid (cSF) leakage, 20
 Cervical cordotomy, percutaneous, 73
 Chain, Ernst Boris, 50
 Chandler, W.F., 2
 Channelrhodopsin-2 gene (ChR2), 14, 15
 Chromophores, 14
 Chronic pain, DBS for, 9
 C25II sonic hedgehog, 126, 128
 Clindamycin/rifampin, catheters impregnated with, 11
 Clinical research
 concept of equipoise, 35–36
 ethical foundation of, 34
 ethical principles of, 35t
 future of, 37–39
 protection of human subjects, 35
 Clinical trials
 ethical challenges to, 35, 36
 neurosurgical, 36
 phase II, 25
 phase III, 25
 frequentist design, 38
 future beyond, 37–39
 prospective designs, 38t
 surgical, 35
 Clinical wisdom
 concept of, 49
 in daily practice, 51
 definition of, 53
 foundation of, 49
 precedence of, 52–53
 teaching of, 51–52
 Clinician-learners, characteristics of, 5
 Clostridial toxin, 13
 Cluster headaches, DBS for, 9
 Cochrane Collaboration, reviews, 29
 Cognitive Experience, licensure and, 46
 Cognitive theories, multimedia learning and, 58, 58
 Coherence principle, 61–62, 61t, 62
 Cold sores, acyclovir for, 74
 Collective experience, definition of, 49
 Collins, James C., 51
 Commercialism, medicine and, 70
 Competency, measurement of, 4
 Computed tomography (CT)
 of arteriovenous malformations, 41
 diagnostic, 41
 visibility of vitamin E capsules, 82
 Concepts, knowledge and, 59
 Confidence intervals, heterogeneity and, 29
 Conflict-of-interest issues, 51
 Confounding by indication, 25
 Congress of Neurological Surgeons, 46, 66
 Congressional Budget Office, 70, 71
 Continuing medical education
 continuing development of, 7
 licensure and, 45–46
 Continuous performance assessments, 5
 Control populations
 for clinical trials, 37
 historical, 26
 instructional methodology studies, 59
 selection of, 26
 Copper sulfate, for fiducials, 80, 83
 Core ideologies, biases and, 50–51
 Corticotropin, elevated, 19
 Cortisol
 serum levels, 19
 urinary free, 19
 Craniotomy, size of, 41
 Creativity
 clinical wisdom and, 49–50
 core ideologies and, 52
 decision making and, 50
 Credé maneuver, 86
Crossing the Quality Chasm (IOM), 46
 Cushing, Harvey, 70

Cushing's disease
 clinical recovery, 21
 imaging results in, 19
 patient presenting with, 18
 pituitary adenomas and, 95–96

D

Dacey, Ralph, 66
 Data
 categories of, 54
 repositories of, 5
 Data analysis
 practice-based learning and, 4
 research design and, 28–29
 Data collection
 performance improvement and, 4
 research design and, 28–29
 DBS. *see* deep brain stimulation (DBS)
 Decision making
 clinical creativity and, 50
 paternalism in, 34
 problem-based, 52
 process of, 52
 Declaration of Helsinki, 34
 Deep brain stimulation (DBS), 9
 closed-loop interfaces, 12–13
 device-centric advancements, 10–11
 electrical field surrounding, 11
 interpreting cerebral activity, 12–13
 lead geometry, current steering and, 11
 optimization of, 9–12
 reduction of infections, 10–11
 state-of-the-art technology, 9–10
 targeting advances, 11–12
 volume of tissue activated, 11
 Department of Health and Human Services, 46–47
 Depression, DBS for, 9
 DICER, siRNA processing by, 107
 Differential diagnoses, concept of, 54
 Digital subtraction angiography, 41
 Diphenylhydantoin, 74
 Discoveries, implementation of, 50
 Donovan, William, 89
 Doppler probes, 120, 120
Drosophila, studies in neuromodulation using, 14
 Dystonia, DBS for, 9

E

Eden, Sonia, 68
 Education. *see also* continuing medical education
 goals of, 3
 residency redesign, 66–69
 teaching of clinical wisdom, 51–52
 Effect size, instructional methodology studies, 60
 Einstein, Albert, 49, 51
 Electrophysical analysis, BAC—transgenic hESC cells, 127

Embryonic stem cells. *see* human embryonic stem cells (hESCs)
 Epidermal growth factor receptor (EGFR), 102
 Equipose, concept of, 35–36, 37
 “Era of Professional Accountability,” 46
 Essential tremor, DBS for, 9
 Estrogens, suppression of IGF-1, 22
 Ethics issues
 in clinical research, 34
 for neurosurgical clinical trials, 36
 principles of clinical research, 35t
 randomization of patients, 54
 Evidence. *see also* medical evidence
 levels of, 55t
 tyranny of, 51
 Evidence-based instruction, 59, 60–65
 Evidence-based medicine
 barriers to adoption of, 55
 collaborative, 7
 decision making and, 51
 incorporation of experience into, 54–56
 medical evidence for, 24–33
 trends toward, 5
 Expert opinions, as evidence, 24
 External validity, of RCTs, 29–30

F

Facts, knowledge and, 59
 Fiberoptic probes, 12
 Fiducials
 cost of, 80–83
 overall accuracy of registration (OAR), 80
 skin, 93
 Financial biases, 51
 Fixed-effects methods, meta-analyses, 29
 Flemming, Alexander, 49–50, 50
 Florey, Howard, 50
 Flow cytometry
 cell culture study, 108–110
 hESC-derived motor neurons, 125–126
 Fluorescence detection endoscopes, 93
 Fluorescence-guided resection (FGR)
 ALA-induced, 93–97
 completeness of resection using, 96
 specificity of, 96
 Fluorescence image-guided surgery (FIGS), 93–97
 Foramen ovale
 anulla penetrating, 75, 75
 percutaneous injection through, 73
Forgive and Remember (Bosk), 35
 FoxP3
 immunohistochemical staining, 99, 99
 prognostic significance of, 98, 100–102, 101t, 101t
 Treg cell expression of
 inhibition of antitumor immunity by, 98
 tumor grade and, 100t
 Frameless stereotaxy. *see also* neuronavigation; Stealth frameless stereotactic system

benefits of, 20–21
 targeting improvements and, 11, 12
 Frequentist trial designs, 38

G

Gabapentin, 74
 Gallium nitride lasers, 93
 γ -aminobutyric acid (GABA), 13
 Gasserian ganglion, injection with alcohol, 73
 Geer, Carol, 68
 Generalizability, of RCTs, 29–30
 Generative processing, fostering of, 64–65, 65t
 Glial fibrillary acidic protein, 15
 Glioblastoma multiformae
 ALA-induced fluorescence, 95, 95
 cell culture lines, 107–108
 fluorescence under blue light, 94
 immunohistochemical staining, 99
 prognosis, 96, 100, 101
 proteasome inhibition for, 107–118, 114f
 under standard light, 94
 Treg/CD4 T cell ratio in peripheral blood, 98
 Glioma tissue microarrays, 99t
 Gliomas
 ALA-induced fluorescence, 95
 immunohistochemical staining, 99
 role of Tregs, 98–106
 Tregs and patient survival, 100–102
 Gliosarcomas, IHC staining, 99
 Globus pallidus
 internal segment of
 deep brain stimulation, 9
 local field potential synchrony, 13
 Glutamatergic acid decarboxylase, 13
 Golden Rule, 53, 53
 Gorelick, Judy, 68
 Government Accountability Office, 70, 71
 GRADE Working Group, 30
 Green fluorescent protein (GFP)
 BAC expressing, 125–130
 motor neuron-specific expression of, 129
 Growth hormone (GH) production, 21

H

Haines, Stephen, 54
 Hamamatsu Orca-ER CCD camera, 110
 Hb9 transcription factor, 125, 129, 130
 Headaches, cluster-type, DBS for, 9
 Health care, social framework of, 71
 Health insurance, costs of, 70
 Health policy, 71
 Healthcare, costs of, 70
 Heterogeneity, measures of, 29
 Historical controls, 26
 Honesty, wisdom and, 50
 Hook effect, 22

Hormone replacement therapy (HRT) studies, 26
 Hospital Quality Alliance (HQA), 47
 Hospitalization, cost of, 70
 Human cognitive structure, 7
 Human embryonic stem cells (hESCs)
 culture of, 125
 directed development of, 130–131
 motor neurons derived from, 125–132
 potential of, 125
 Human subjects
 concept of equipoise, 35–36
 protection of, 35
 Hyperthyroidism, primary, 18–19
 Hypocortisolism, presentation, 19
 Hypophysitis, treatment of, 18
 Hypothyroidism
 clinical, screening for, 18
 primary, 18
 pseudotumor, 18

I

Ideas, generation of, 50
 Immunofluorescence studies, 127
 Infections, postoperative
 DBS-related, 10–11
 Inferior petrosal sinus sampling, 19
 Inflammatory responses, CB₂ receptor and, 85
 Information literacy, 5
 Informed consent, 35, 38
 Innovation
 clinical wisdom and, 49–50
 fostering of, 50
 process of, 50
 Institute of Medicine (IOM), 46
 Instruction
 definition of, 58
 evidence-based, 59
 methods research, 59
 objectives, 58–59
 process of, 59
 reducing extraneous processing, 61–63
 science of, 58–60
 Instrumental variables, 27
 Insulin-like growth factor 1 (IGF-1), 21
 suppression of, 21, 22
 Integrating, process of, 58
 Intellectual bias, 51
 Intent-to-treat analyses, 28
 Interleukin-2, 102
 Interleukin-10, 102
 Internal pulse generators (IPGs)
 cranially-mounted, 10
 for deep brain stimulation, 9–10
 infraclavicular, 10
 longevity of, 11
 placement, 10
 postoperative infections, 10–11

Intracranial lesions
 identification using ALA, 93–97
 localization using ALA, 93–97
 resection using ALA, 93–97
 Intraparenchymal cerebral hemorrhages, 44
 Investigational devices, exemption studies, 51
 Investigator bias, 51
 Ionizing radiation
 sensitivity screen, 108, 109
 sensitization to, 111–114

J

Janus kinases/signal transducers and activator of transcription 3 (JAK/STAT3) pathway, 102
 Joint Commission on the Accreditation of Healthcare Organizations (JCAHO), 46, 47
 Justice, principle of, 34, 35t

K

Kerr-Jakoby, Ruth, 68
 Kerrisoni punches, 20
 Killian speculum, 19
 Kinetra DBS IPG, 11
 Kir2.1 channel, 13
 Knowledge
 collective generation of, 6
 components of, 3
 definition of, 49
 experience and, 53
 explosion of, 3
 gaps in, 3
 instructional objectives, 58–59
 kinds of, 59
 medical, 3
 Knowledge management, 2–8
 Knowledge societies, 2–8
 Kolb, David, 4, 4, 49, 52

L

Labor unions, 47
 Lactacystin, cell culture studies, 108
 Lanreotide (Somatuline Depot), 21
 Learning theory, tenets of, 2–3
 Leapfrog Group, 46
 Learners
 active learning by, 57
 adult, 3–4
 clinicians as, 5
 communities of, 5
 empowerment of, 2
 instruction centered on, 58
 mentors for, 45
 roles of, 57
 Learning
 definition of, 57

enlightened, 2–8
 essential processing, 63–64
 in a knowledge society, 2–8
 meaningful, 59
 outcomes, 59
 performance improvement and, 3
 practice-based, 4–5
 principles of, 57–58
 process of, 57–58
 by rote, 59
 science of, 57–65
 self-directed, 3
 support from learning programs, 4–5
 systems
 key initiatives, 7
 role of teachers in, 2
 Learning programs, barriers to, 6
 Learning Sciences, function of, 2
 Lehmann, Emily, 68
 Lesioning, neuromodulation using, 9
 Lesions, pituitary, 18
 Levothyroxine replacement, 18
 Licensure and Professional Standing, 45
 Lifelong Learning and Self-assessment, 45–46
 Light, neuromodulation by, 14
 Lightning, formation of, 60, 61
 Lindeman, Eduard, 7, 7
 Live cell imaging, 110–111
 Local field potential (LFP) synchrony, 13
 Logical empiricism, 49
 Long-term memory, 58
 Lumbar disc herniation, 55

M

Magnetic resonance imaging (MRI)
 arteriovenous malformations, 41
 surgical outcomes, 42, 42t, 43
 diagnostic, 41
 imaging deep nuclei, 11
 pituitary gland, 20
 surgical planning and, 93
 visibility of vitamin E capsules, 81
 Maintenance of Certification (MOC), 5, 45–46
 Malignant gliomas, classification, 26–27. *see also* gliomas
 Mammosomatotrophic tumors, 21
 Market pressures, forms of, 51
 Matching, of controls, 26
 Meckel's cave, 76
 Medical evidence
 classification of, 24
 clinical wisdom and, 51
 definitions of, 24–33
 hierarchy of, 24, 25t
 moving to recommendations, 29–30
 Medical liability insurance, 70
 Medicare
 impact on the federal budget, 70–71

Payment Advisory Commission, 70, 71
 payment policies, 70
 scheduled fee cuts, 70
 trustees, 70
 Medtronic 3387, 9
 Medtronic 3389, 9
 Memory, types of, 58
 Meningiomas, ALA-induced fluorescence, 95
 Mentors, learning experience and, 45
 MER, electrode placement, 12
 Meta-analyses
 as evidence, 25
 of individual patient data, 29
 steps in, 28–29
 Metacognition
 clinical wisdom and, 53
 definition, 3
 skills needed for, 3
 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, 13
 Methylprednisolone, for spinal cord injury, 84
 Microelectrode targeting, intraoperative, 11
 Micropore adhesive tape, 81
 Microscope photodiagnosis system (PDS), 93
 Milk fat, for fiducials, 80, 83
 Miller, Carol, 68
 Minimally conscious state, DBS for, 9
 Mixed oligoastrocytomas, IHC staining, 99
 Modality principle, essential processing, 63t, 64, 64
 Molière, 52
 Motor neurons
 differentiation of, 125–126
 electrophysical analysis, 128
 enrichment via cell sorting, 128
 GFP expression, 129
 human stem cell-derived, 125–132, 126, 128
 postsort culture of, 126
 spinal, 131
 transcriptome analysis, 128–130, 131
 MTT Viability Assay Kit, 108
 Multimedia learning
 animation on lightning formation, 60, 61, 61
 cognitive theory of, 58, 58
 evidence-based principles of, 60–65
 fostering generative processing, 64–65
 lesson design, 60
 in neurosurgery education, 57
 role of technology in, 58
 seductive details, 61
 Multimedia principle, generative processing and, 64–65, 65t
 Multiple myelomas, ALA-induced fluorescence, 95
 Multivariate analysis, controls, 26
 Muraszko, Karin, 68

N

National Acute Spinal Cord Injury Study, 55
 National Board of Medical Examiners, 45
 National Committee on Quality Assurance, 46, 47

National Quality Forum, 47
 Neomycin/polymyxin solution, prophylactic, 10
 Neuromodulation
 advances in, 9–17
 biologics-based, 13–15
 optogenetics, 14–15
 Neuronavigation. *see also* frameless stereotaxy; Stealth frameless
 stereotactic system
 fiducials, 80–83
 Neuropace responsive neurostimulator, 10
 Neuroprotection, CB receptors and, 84–92
 Neurosurgeons, advocacy role of, 71
 Neurosurgery
 definition of quality in, 45–48
 economic forces against, 70–71
 medical education in, 57
 medical school experience, 45
 postgraduate years, 66
 residency experience, 45
 residency redesign, 66–69
 Nietzsche, Friedrich, 50–51, 52
 Nikon Plan Fluor objective, 110
 Nikon TE2000E PFS microscope, 110
 Noninferiority design, 38–39
 NpHR channel, 15

O

Obesity, DBS for, 9
 Observational studies
 selection of control populations, 26
 unpredictability paradox, 27
 Observations, as evidence, 25
 Obsessive-compulsive disorder, DBS for, 9
 Occipital electrodes
 migration of, 119
 positioning of, 121
 Occipital nerve stimulation
 complications, 122
 electrodes, 119, 121
 intraoperative photographs, 121
 for occipital neuralgia, 119–124
 operative technique, 119, 120
 outcomes, 121–122, 123t
 patient demographics, 122t
 patient positioning, 120
 patient selection, 119
 postoperative skull x-ray, 121
 stimulation parameters, 122t
 Occipital neuralgia (ON)
 definition of, 119
 occipital nerve stimulation for, 119–124
 patient demographics, 122t
 Octreotide (Sandostatin LAR), 21
 Oligodendromas, IHC staining, 99
 Operating room setups, TGN treatment, 74
 Opportunity, clinical wisdom and, 49–50
 Optic chiasm, elevation of, 20

Optical biopsy system (OBS), 93–94, 94
 Organizing, process of, 58
 Osler, William, 2, 6, 6, 7, 50
 Outcomes, optimization of, 51
 Overall accuracy of registration (OAR), 80
 Oxycarbazepine, for trigeminal neuralgia, 74

P

P53 status, 107, 112–113, 115
 Paige, Satchel, 53
 Parasellar lesions, 19t, 22
 Parkinson's disease, DBS for, 9, 13
 Pasteur, Louis, 49
 Paternalism, decision making and, 34
 PathFinder surgical robotic system, 93
 Patient-centric approaches, 51
 Patient positioning, for TGN treatment, 75
 Patients
 autonomy of, 34
 selection of
 biases, 51
 for occipital nerve stimulation, 119
 for trigeminal balloon compression, 74
 sham surgeries, 35
 Pay-for-performance bonuses, 70
 Pegvisomant (Somavert), 21
 PEP-3-KLH/CDX-110, 103, 104
 Percutaneous balloon compression, for TGN, 73–79
 outcomes, 77
 postoperative management, 77
 recurrence rates, 77
 technique, 74–77
 Percutaneous occipital electrodes, migration of, 119
 Performance improvement. *see also* quality
 practice-based learning and, 4
 self-directed learning and, 3
 Personalization principle, 65, 65t
 Petrosal sinus sampling, 21
 Petrous bone, 76
 Photo bleaching, of PpIX fluorescence, 96
 Physician-patient communications, 34, 35
 Physicians, decision making by, 34
 Physician's Consortium for Performance Improvement Program (AMA), 46
 Pituitary adenomas
 age at diagnosis, 18
 ALA-induced fluorescence, 95
 incidence of, 18
 microadenomas, 19
 outcomes, 21
 resectioning, 19
 prolactin-secreting, 22
 race and, 18
 Pituitary-adrenal axis, assessment, 19
 Pituitary gland
 enlarged, 20
 lesions
 parasellar, 19t
 presentation of, 18
 sellar, 19t
 microadenomas, 19
 treatment for disorders of, 18–22
 Placebo effects, 35
 Polymerase chain reactions, 127, 130
 Popp, John, 66
 Porras, Jerry I., 51
 Potassium ion channels, Kir2.1, 13
 Practice-based data, repositories of, 5
 Practice-based learning, 4
 activities involved in, 4
 application of, 4–5
 the knowledge society and, 6
 Practice Performance Assessment, 46
 Prednisone, for hypophysitis, 18
 Preproenkephalin gene, 13
 Pressure monitors, digital, 75
 Pretraining principle, essential processing and, 63, 63t, 64
 Primary central lymphoma, ALA-induced fluorescence, 95
 Procedures, knowledge and, 59
 Professional interactions, learning through, 5
 Prognostic factors
 meta-analyses and, 25
 multivariate analysis, 26
 Prolactin, measurement of, 22
 Prolactinomas, treatment, 22
 Propensity scores, 27
 Proteasome inhibitors
 function of, 107
 for GBM, 107–118, 114f
 sensitizing effect of, 108, 111–112, 116
 Proteasomes, composition of, 107
 Protophoryin-IX (PpIX), 93–97
 photo bleaching of, 96
 PSMA (prosome, macropain subunit, alpha type 1) silencing, 111–114
 Public opinion, on healthcare quality, 47
 Publication bias, 26, 29, 51

Q

QIAGEN DNA repair siRNA library, 111
 Quality
 “beholders” of, 46–47
 in medicine, 45
 in neurosurgical practice, 45–48
 Quality Alliance Steering Committee, 47

R

Radiation therapy
 in acromegaly, 21
 for GBM, 107
 Radiation Therapy Oncology Group, 26–27
 Radiofrequency (RF) antennae, 9
 Radiofrequency (RF) generators, 73
 Radionics, Inc., 73
 Radiosurgery, for AVMs, 41

Random-effects method, meta-analyses, 29
 Randomization, instructional methodology studies, 59
 Randomized controlled trials (RCTs)
 blinding, 27
 clinical problems addressed by, 54
 completeness of follow-up, 27–28
 ethics of randomization, 54
 as evidence, 24
 external validity of, 29–30
 generalizability of, 29–30
 phase III, 27–28
 surgical
 special problems with, 28
 timing of, 28
 treatment allocation, concealment of, 27
 Recommendations, from evidence to, 29–30
 Recursive Partitioning Analysis classification, 26–27
 Redundancy principle, 61t, 62, 62
 Reflex hypertension, trigeminal nerve compression and, 74
 Regulatory bodies, data collection by, 4
 Regulatory T cells (Tregs)
 FoxP3 positive, 98
 frequency in gliomas, 98–100
 incidence in gliomas, 98–100
 inhibition of antitumor immunity by, 98
 inhibition with STAT3 blockade, 102–105
 role in human glioma patients, 98–106
 Research designs
 adaptive design, 38
 with animal models, 85–87
 bayesian design, 38
 blinding in, 27
 completeness of follow-up, 27–28
 control populations, 26
 crossover designs, 28
 ethics issues, 34
 frequentist design, 38
 historical basis of ethics in, 34–35
 instructional method studies, 59
 meta-analyses, 28–29
 noninferiority design, 38
 observational case series, 25–27
 patient numbers needed for, 37, 38
 for phase III trials, 38t
 prospective, 38t
 protection of human subjects, 35
 reduction of bias in, 27
 spinal cord injury study, 85–87
 systematic reviews, 28–29
 target populations, 37
 treatment allocation concealment, 27
 Zelen design, 37–38
 Residency
 core curricula, 66–67
 postgraduate years, 66
 redesign of, 66–69
 six year format, 66

Residency Review Committee, 45, 66
 Restore IPG option, 11
 RestoreUltra spinal cord stimulator, 11
 Retinoic acid, 125–126, 128
Rhodopsin gene, 14
 Rifampin/minocycline, equipment impregnated with, 11
 RISC (RNA-inducing silencing complex), 107
 Risk stratification scores, 26–27
 Rogers, Carl, 3, 3
 Rota Rod testing, of mice, 86, 88, 89

S

Sackett, David, 51
 SANS Lifelong Learning, 6
 SANS (Self-Assessment in Neurological Surgery), 46
 Segmenting principle, in essential processing, 63–64, 63t
 Selecting, process of, 58
 Selection bias, 25–26, 51
 Self-assessment, practice-based learning and, 4
 Self-Assessment in Neurological Surgery, 5
 Self-directed learning, 3
 Self-reflection, wisdom and, 52
 Sella
 lesions, 19t
 opening of, 20
 reconstruction of, 20
 visualization of, 19
 Sensory memory, 58
 Sham surgeries, 35
 Signaling principle, extraneous processing and, 61t, 62
 Small interference RNA (siRNA)
 proteasome inhibition using, 107–118
 screening use of, 108, 111–114, 112
 Society of Neurological Surgeons, 66, 67, 70
 Soletra IPG, 10
 Soletra unilateral DBS IPG, 11
 Somatomedin C. *see* insulin-like growth factor 1 (IGF-1)
 Somatostatin analogues, 21
 Sonic hedgehog, cell culture using, 126, 128
 Spasme cinique. *see* trigeminal neuralgia
 Spatial contiguity principle, extraneous processing and, 61t, 62–63, 63
 Spetzler-Martin classification of AVMs, 40
 distribution of patients based on, 42t
 outcomes and, 41–44
 surgical results, 42, 42t, 43t, 44t
 treatment strategies and, 41t
 Spinal cord injury (SCI)
 clinical trial, 55
 costs of, 84
 iatrogenic, 0
 incidence of, 84
 neuroprotective agents, 89–91
 research designs, 85–87
 Spine Patient Outcomes Research Trial, 55
 SR141716, 85
 STAT3 (signal transducer and activator of transcription 3), 102–105

Statistical inference, principle of, 38
 Stealth frameless stereotactic system, 20, 21. *see also* neuronavigation
 StealthStation, 80–83, 93
 Steroids, high-dose, 84
 Strahle, Jennifer, 68
 Strategies, knowledge and, 59
The Student Life (Osler), 6
 Substantia nigra, neuronal death in, 13
 Subthalamic nucleus (STN)
 deep brain stimulation, 9
 local field potential synchrony, 13
 targeting advances, 12
 Supratentorial arteriovenous malformations, 40–44
 Synaptic transmission, modification of, 13–14
 Synaptobrevin, 13

T

T cells. *see also* regulatory T cells (Tregs)
 CD4, proliferation of, 98
 CD8, in gliomas, 99
 cytotoxic/regulatory ratio, 101
 immunohistochemical staining, 99
 WHO grade tumors and, 100
 Tasks, knowledge and proficiency for, 59
 Technology
 costs of care and, 70
 instruction centered on, 58
 knowledge management and, 2
 Temozolomide (TMZ)
 cell culture studies, 108
 cell fate after Velcade and, 113–114
 effect on U87 cell xenografts, 114, 115
 efficacy in GBM, 107
 growth arrest study, 110
 inhibition of Treg trafficking, 102
 p53 status and, 112–113
 sensitivity screen, 108, 109
 sensitization by proteasome inhibition, 112–113, 113, 116
 sensitization to, 111–114, 114f
 Temporal contiguity principle, extraneous processing and, 61t, 63
 Thermocoagulation, 73
 Third-party payers, data collection by, 4
 Thyroid pseudotumor (hyperplasia), 18
 Thyroid-stimulating hormone (TSH), 18
 Thyroxine (T₄), in primary hypothyroidism, 18
 Tic douloureux. *see* trigeminal neuralgia
 Tissue glue, use of, 20
To Err Is Human (IOM), 46
 Tourette's syndrome, DBS for, 9
 Transcriptome analysis, 127, 131
 Transforaminal balloon, 73
 Transgenes, in neuromodulation, 13–14
 Transnasal approach, in microadenomas, 19–20
 Transsphenoidal approach, extended, 22
 Treatments
 allocation in research studies, 27
 effectiveness studies, 30

 efficacy of, 30
 evidence-based medicine and, 54
 Tregs. *see* regulatory T cells
 Trigeminal depressor responses, 74
 Trigeminal neuralgia (TGN)
 operating room setup, 74
 percutaneous balloon compression for, 73–79
 postoperative management, 77
 treatment of, 74
 trigger points, 73
 Trigeminal roots, biopsy of, 73
 Tumors
 Treg cells in, 98
 WHO grade, 100
 Tuskegee study, 34

U

U87MG cell studies, 107–114
 Unpredictability paradox, 27

V

Validity, of RCTs, 29–30
 Velcade (bortezomib)
 cell culture studies, 108
 cell fate after TMZ and, 113–114
 delayed treatment with, 113–114
 effect on U87 cell xenografts, 114, 115
 growth arrest study, 110
 sensitizing effect of, 116–117
 TMZ treatment with, 113
 tumoricidal activity, 111
 Venes, Joan, 68
 Ventral intermediate nucleus of the thalamus, DBS, 9
 Ventricular drains, antibiotic-impregnated, 11
 Vitamin E capsules, 80, 80–82, 81, 82
 Vogelbaum, M.A., 37–39
 Voltaire, 52
 Volume of tissue activated (VTA), 11

W

Web 2.0 movement, 5
 Weiss, Kevin, 46
 Wiki, learning and, 5
 WIN 55,212–2, 85
 Wisdom, the concept of, 49–53
 Women, in neurosurgery, 68, 68
 Working memory, 58
 World Medical Association, 34
 Worst-case sensitivity analyses, 28
 WP1066, 102, 103

Y

Yang, Lynda, 68

Z

Zelen design, for research, 37–38